These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 36036563)

  • 21. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological and genomic comparisons between different histologic components in combined small cell lung cancer and non-small cell lung cancer.
    Lin MW; Su KY; Su TJ; Chang CC; Lin JW; Lee YH; Yu SL; Chen JS; Hsieh MS
    Lung Cancer; 2018 Nov; 125():282-290. PubMed ID: 30429033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
    Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
    Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
    Liu Y
    Cancer Biol Ther; 2018 Jun; 19(6):445-449. PubMed ID: 29461911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comprehensive analysis of treatment modes and clinical outcomes of small cell lung cancer transformed from epidermal growth factor receptor mutant lung adenocarcinoma.
    Wang S; Xie T; Hao X; Wang Y; Hu X; Wang L; Li Y; Li J; Xing P
    Thorac Cancer; 2021 Oct; 12(19):2585-2593. PubMed ID: 34490724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Sequential occurrence of small cell and non-small lung cancer in a male patient: Is it a transformation?
    Wahab A; Kesari K; Chaudhary S; Khan M; Khan H; Smith S; Boumber Y
    Cancer Biol Ther; 2017 Dec; 18(12):940-943. PubMed ID: 29157085
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Treatment of Brain Metastases of Non-Small Cell Lung Carcinoma.
    Rybarczyk-Kasiuchnicz A; Ramlau R; Stencel K
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33435596
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
    Gelatti ACZ; Drilon A; Santini FC
    Lung Cancer; 2019 Nov; 137():113-122. PubMed ID: 31568888
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of nintedanib plus docetaxel in patients with refractory advanced epidermal growth factor receptor mutant lung adenocarcinoma.
    Riudavets M; Bosch-Barrera J; Cabezón-Gutiérrez L; Diz Taín P; Hernández A; Alonso M; Blanco R; Gálvez E; Insa A; Mielgo X; Morán T; Ponce S; Roa D; Sánchez JM; Majem M
    Clin Transl Oncol; 2021 Dec; 23(12):2560-2567. PubMed ID: 34292495
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unexpected favorable outcome to etoposide and cisplatin in a small cell lung cancer transformed patient: a case report.
    Xie Z; Gu Y; Lin X; Ouyang M; Qin Y; Zhang J; Liu J; Mai S; Zhou C
    Cancer Biol Ther; 2019; 20(9):1172-1175. PubMed ID: 31161851
    [TBL] [Abstract][Full Text] [Related]  

  • 31. ALK fusion small cell transformation of lung adenocarcinoma: A case report and literature review.
    Xu G; Zhou L
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2024 Apr; 49(4):628-636. PubMed ID: 39019792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFR-mutant lung adenocarcinoma.
    Popat S; Wotherspoon A; Nutting CM; Gonzalez D; Nicholson AG; O'Brien M
    Lung Cancer; 2013 Apr; 80(1):1-4. PubMed ID: 23312887
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Histologic transformation to small-cell lung cancer following gefitinib and radiotherapy in a patient with pulmonary adenocarcinoma.
    Fiore M; Trecca P; Perrone G; Amato M; Righi D; Trodella L; D'Angelillo RM; Ramella S
    Tumori; 2019 Dec; 105(6):NP12-NP16. PubMed ID: 30799776
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Histological Transformation after Acquired Resistance to the Third-Generation EGFR-TKI in Patients with Advanced
    Lee PH; Huang YH; Lin H; Hsu KH; Chen KC; Tseng JS; Chang GC; Yang TY
    Medicina (Kaunas); 2022 Jul; 58(7):. PubMed ID: 35888627
    [No Abstract]   [Full Text] [Related]  

  • 35. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma.
    Watanabe S; Sone T; Matsui T; Yamamura K; Tani M; Okazaki A; Kurokawa K; Tambo Y; Takato H; Ohkura N; Waseda Y; Katayama N; Kasahara K
    Lung Cancer; 2013 Nov; 82(2):370-2. PubMed ID: 24012411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transformation to small cell lung cancer as an acquired resistance mechanism in EGFR-mutant lung adenocarcinoma: a case report of complete response to etoposide and cisplatin.
    Hwang KE; Jung JW; Oh SJ; Park MJ; Shon YJ; Choi KH; Jeong ET; Kim HR
    Tumori; 2015 Jun; 101(3):e96-8. PubMed ID: 25908039
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Transformation to small cell lung cancer is irrespective of EGFR and accelerated by SMAD4-mediated ASCL1 transcription independently of RB1 in non-small cell lung cancer.
    Ding X; Shi MX; Liu D; Cao JX; Zhang KX; Zhang RD; Zhang LP; Ai KX; Su B; Zhang J
    Cell Commun Signal; 2024 Jan; 22(1):45. PubMed ID: 38233864
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Mechanism exploration and model construction for small cell transformation in EGFR-mutant lung adenocarcinomas.
    Li Y; Xie T; Wang S; Yang L; Hao X; Wang Y; Hu X; Wang L; Li J; Ying J; Xing P
    Signal Transduct Target Ther; 2024 Oct; 9(1):261. PubMed ID: 39353908
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients.
    Kuiper JL; Heideman DA; Thunnissen E; Paul MA; van Wijk AW; Postmus PE; Smit EF
    Lung Cancer; 2014 Jul; 85(1):19-24. PubMed ID: 24768581
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.